Therefore, the ROS-NOXA-MCL-1 axis in response to VK2 appears to be attributed to VEN sensitization in AML cells, which appears to be the underlying molecular mechanism of the high response rate in our clinical outcomes (Table 2, Fig 1). The gene discussed is PMAIP1; the disease is acute myeloid leukemia.